Scienture Holdings Raises $3.9M in Registered Direct Offering.

Scienture Holdings has entered into a securities purchase agreement with institutional investors to buy 3.2 million shares of common stock at $1.20 per share, raising approximately $3.9 million before deducting fees and expenses. The offering is expected to close on August 15, 2025, with Maxim Group acting as sole placement agent.

Commack, NY, Aug. 14, 2025 — Scienture Holdings, Inc. (Nasdaq: SCNX), a holding company focused on developing and distributing novel specialty pharmaceutical products, has announced the pricing of a registered direct offering of 3,225,000 shares of common stock. The offering is priced at $1.20 per share, with gross proceeds expected to be approximately $3.9 million before deducting placement agent fees and other offering expenses [1].

The offering is being conducted under an effective shelf registration statement on Form S-3 (File No. 333-289198), previously filed with the U.S. Securities and Exchange Commission (SEC) on August 1, 2025, and declared effective on August 8, 2025. The shares will be offered only by means of a prospectus, with a prospectus supplement and accompanying prospectus to be filed with the SEC and available on the SEC’s website at www.sec.gov [1].

Maxim Group LLC is acting as the sole placement agent for the offering, which is expected to close on August 15, 2025, subject to customary closing conditions [1]. Investors interested in obtaining a copy of the prospectus supplement and accompanying prospectus can contact Maxim Group LLC at 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Prospectus Department, or by telephone at (212) 895-3745 or by email at syndicate@maximgrp.com [1].

Scienture Holdings, Inc. is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians, and caregivers by offering unique specialty products to satisfy unmet market needs. The company’s wholly owned subsidiary, Scienture, LLC, consists of a highly experienced team of industry professionals dedicated to developing and bringing to market novel specialty products [2].

This press release contains certain forward-looking statements, including statements regarding the Company’s expectations, hopes, beliefs, intentions, and strategies regarding the future, including the success of products it may launch and the marketplace. These forward-looking statements are subject to a number of risks and uncertainties, including the Company’s ability to satisfy closing conditions for the registered direct offering, risks relating to agreements with third parties, and the outcome of any current legal proceedings or future legal proceedings that may be instituted against the Company [1].

For more information, please visit www.scienture.com.

References:
[1] https://www.globenewswire.com/news-release/2025/08/14/3133508/0/en/Scienture-Holdings-Inc-Announces-Pricing-of-3-9-Million-Registered-Direct-Offering-of-Common-Stock.html
[2] https://finance.yahoo.com/news/scienture-holdings-inc-announces-pricing-130000731.html